Zentalis Pharmaceuticals (ZNTL) Leases (2019 - 2026)

Zentalis Pharmaceuticals has reported Leases for 8 years, with the latest figure at $25.6 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 19.83% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $25.6 million (down 19.83% YoY), and the FY2025 full-year result was $26.3 million, down 19.24% from the prior year.
• Leases for Q1 2026 stood at $25.6 million, down from $26.3 million in the prior quarter.
• The five-year high for Leases was $43.6 million in Q1 2022, with the low at $25.6 million in Q1 2026.
• Average Leases over 5 years is $35.1 million, with a median of $34.7 million recorded in 2024.
• Year-over-year, Leases soared 6053.82% in 2022 and slipped 19.83% in 2026.
• Tracing ZNTL's Leases over 5 years: stood at $42.4 million in 2022, then declined by 15.24% to $35.9 million in 2023, then decreased by 9.43% to $32.5 million in 2024, then slipped by 19.24% to $26.3 million in 2025, then decreased by 2.57% to $25.6 million in 2026.
• The last three Leases figures came in at $25.6 million (Q1 2026), $26.3 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.

Peer Comparison